Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know

Download All
Join the experts at this live webinar as they discuss leveraging the cardioprotective effects of SGLT2 inhibitors to reduce heart failure risk in your patients with type 2 diabetes.
Jennifer B. Green, MD
Mikhail N. Kosiborod, MD

Downloadable Slideset

Expert faculty discuss the latest data on using SGLT2 inhibitors to reduce HF risk in patients with T2D

Jennifer B. Green, MD Mikhail N. Kosiborod, MD Released: June 7, 2021

On Demand Webcast

On-demand webinar on leveraging the cardioprotective effects of SGLT2 inhibitors to reduce heart failure risk in your patients with type 2 diabetes.

Jennifer B. Green, MD Mikhail N. Kosiborod, MD Released: June 21, 2021

ClinicalThought

Expert faculty discusses why healthcare professionals should be vigilant in assessing for HF in patients with T2D and the evolving use of SGLT2 inhibitors in these patients.

Jennifer B. Green, MD Released: June 22, 2021
Provided by the Endocrine Society

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue